December 2017PDF


Breast Cancer

Pfizer’s talazoparib extends PFS in phase III trial in metastatic breast cancer

The phase III EMBRACA trial in patients with germline BRCA1/2-positive locally advanced and/or metastatic breast cancer demonstrated superior progression-free survival in patients treated with talazoparib, compared to patients who received physician’s choice standard of care chemotherapy.



Juno Therapeutics and Celgene release additional data from TRANSCEND trial

Juno Therapeutics Inc., a biopharmaceutical company developing cellular immunotherapies for the treatment of cancer, released additional data from the TRANSCEND study of JCAR017 (lisocabtagene maraleucel; liso-cel) in patients with relapsed or refractory aggressive B-cell non-Hodgkin lymphoma in a presentation at the 59th American Society of Hematology Annual Meeting and Exposition.



Phase III study of venetoclax in combination with rituximab meets primary endpoint

MURANO, a randomized phase III study sponsored by Abbvie, showed that patients with relapsed or refractory chronic lymphocytic leukemia achieved significantly prolonged median progression-free survival with Venclexta/Venclyxto (venetoclax) in combination with Rituxan (rituximab) [median PFS, not reached], compared with bendamustine in combination with Rituxan [median PFS, 17.0 months; hazard ratio, 0.17; 95% CI, 0.11–0.25; P<0.0001].


Kidney Cancer

Genentech’s Tecentriq and Avastin reduce the risk of disease worsening or death from RCC


Skin Cancer

PD-1 antibody cemiplimab demonstrates 46.3% ORR in advanced cutaneous squamous cell carcinoma


Head and Neck Cancer

Galera Therapeutics reports statistically significant results in a 223-patient phase IIb trial of GC4419 for oral mucositis in head and neck cancer


Lung Cancer

Aggressive surgery is best treatment option for early stage lung cancer


Side Effects

Daily oral edoxaban met primary endpoint in Hokusai-VTE cancer study


Liquid Biopsy

Liquid biopsy results differed substantially between two providers in a study


NCI CTEP-Approved Trials for December

December 2017
November 2017PDF


Hematologic malignancies

CD22 CAR-T therapy shows results in leukemia study

A new type of CAR-T therapy that targets the protein CD22 helped achieve remission in nearly 60 percent of leukemia patients who had failed or relapsed on other treatments, according to a paper published in Nature Medicine.



Mount Sinai researchers develop first mathematical model for predicting patient response to immunotherapy

Researchers at the Icahn School of Medicine at Mount Sinai have created the first mathematical model that can predict how a cancer patient will benefit from certain immunotherapies, according to a study published in Nature.


Lung cancer

Phase III study shows Tecentriq and Avastin plus chemo reduced risk of disease progression or death in advanced lung cancer

Genentech said the phase III IMpower150 study met its co-primary endpoint of progression-free survival and demonstrated that the combination of Tecentriq (atezolizumab) and Avastin (bevacizumab) plus chemotherapy (paclitaxel and carboplatin) provided a statistically significant and clinically meaningful reduction in the risk of disease worsening or death compared to Avastin plus chemotherapy in the first-line treatment of people with advanced non-squamous non-small cell lung cancer.


Breast Cancer

Novartis reports positive results from phase III trial of Kisqali for advanced or metastatic breast cancer


Genitourinary cancers

Clinical data for CXCR4 inhibitor, Inlyta showa 29% ORR in clear cell renal cell carcinoma


Brain tumors

Ziopharm announces positive updated results of Ad-RTS-hIL-12 study in brain cancer


NCI CTEP-Approved Trials for November


Regulatory actions

FDA approves adjuvant indication for Sutent in renal cell carcinoma

December 2017
October 2017PDF


Lung cancer

Researchers confirm IASLC proposed characterization of uncertain R Status R(un), prognosis between R0 and R1

A recent study confirmed the International Association for the Study of Lung Cancer’s proposed criteria for uncertain resection margin status, R(un), in residual tumor (R) classification.


Breast cancer

Trastuzumab for HER-2-expressing tumors needn’t delay breast reconstruction

Treatment with trastuzumab (Herceptin/Genentech) of breast cancers that express the HER-2 protein does not increase the risk for complications at the surgical site for women who undergo immediate breast reconstruction after mastectomy.


Brain Cancer

Local radiation provides comparable control of brain metastases compared to surgery

An analysis led by researchers at Fox Chase Cancer Center in collaboration with the European Organization for the Research and Treatment of Cancer found that treating cancer that has metastasized to the brain with focal, high-dose radiation yields improved early results compared with surgical removal.



Cleveland Clinic study: timing of melanoma diagnosis, treatment critical to survival


Prostate Cancer

Pfizer, Astellas report positive results from trial of Xtandi in non-metastatic castration-resistant disease


Kidney Cancer

Argos Therapeutics reports interim analysis of phase III ADAPT trial


NCI CTEP-Approved Trials for October


Regulatory actions

FDA approves Kite’s CAR-T cell therapy; another win for NCI’s intramural program

November 2017
Page 1 of 1612345678910...Last »